Oncotarget

Research Papers:

Serum IL-33 level is a predictor of progression-free survival after chemotherapy

Wenwei Hu, Chen Wu, Xiaodong Li, Zhuojun Zheng, Quanqin Xie, Xu Deng, Jingting Jiang and Changping Wu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35116-35123. https://doi.org/10.18632/oncotarget.16627

Metrics: PDF 1613 views  |   HTML 1358 views  |   ?  


Abstract

Wenwei Hu1,2,3,*, Chen Wu1,2,3,*, Xiaodong Li1,2,3,*, Zhuojun Zheng2, Quanqin Xie2, Xu Deng2, Jingting Jiang2,3 and Changping Wu1

1Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China

2Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China

3Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu Province, China

*These authors should be considered as co-first authors

Correspondence to:

Changping Wu, email: wcpjjt@163.com

Jingting Jiang, email: jiangjingting@suda.edu.cn

Keywords: IL-33, gastric cancer, chemotherapy, decline extent, progression-free survival

Received: February 03, 2017     Accepted: March 02, 2017     Published: March 28, 2017

ABSTRACT

This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemotherapy patients and healthy subjects, respectively. sIL-33 levels were 131.9 (95% CI 105.9-184.9) pg/mL, 95.1 (95% CI 70.8-140.2) pg/mL and 95.7 (95% CI 73.3-114.3) pg/mL in pre-chemotherapy patients, post-chemotherapy patients and controls, respectively. The sIL-33 level in pre-chemotherapy patients was significantly higher than that in both post-chemotherapy patients and controls (P < 0.001 and P < 0.001, respectively). There was no statistically significant difference between the sIL-33 levels in post-chemotherapy patients and controls (P > 0.05). PFS in patients with the decline extent > 30.1% (median PFS not reached) was statistically significant longer than that (median PFS 7 months, 95% CI 1.569 - 12.431) in patients with the decline extent ≤ 30.1% (P = 0.003). The decline extent of sIL-33 level (> 30.1%) was associated with longer PFS (P = 0.006). Distant metastasis was associated with the decline extent of sIL-33 level (P = 0.034). The decline extent of sIL-33 after chemoresistance could be regarded as a predictor of the PFS of GC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16627